- 5 Ergebnisse
Kleinster Preis: € 16,20, größter Preis: € 111,22, Mittelwert: € 68,15
1
Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - Trifilieff, Alexandre
Bestellen
bei booklooker.de
€ 94,40
Versand: € 0,001
Bestellengesponserter Link
Trifilieff, Alexandre:

Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - gebunden oder broschiert

2013, ISBN: 9783034807081

[ED: Gebunden], [PU: Springer Basel], Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an … Mehr…

Versandkosten:Versandkostenfrei, Versand nach Deutschland. (EUR 0.00) preigu
2
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)
Bestellen
bei Amazon.de (Intern. Bücher)
€ 100,92
Versand: € 3,001
Bestellengesponserter Link
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy) - gebunden oder broschiert

2013, ISBN: 9783034807081

Springer, Gebundene Ausgabe, Auflage: 2014, 153 Seiten, Publiziert: 2013-11-27T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 20 black & white illustrations, 21 colou, 7.97 kg, Pharmakol… Mehr…

Versandkosten:Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00)
3
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)
Bestellen
bei Amazon.de (Intern. Bücher)
€ 16,20
Versand: € 3,001
Bestellengesponserter Link
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy) - gebunden oder broschiert

2013

ISBN: 9783034807081

Springer, Gebundene Ausgabe, Auflage: 2014, 153 Seiten, Publiziert: 2013-11-27T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 20 black & white illustrations, 21 colou, 7.97 kg, Pharmakol… Mehr…

Versandkosten:Auf Lager. Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) lange_und_springer_antiquariat
4
Bestellen
bei AbeBooks.de
€ 18,00
Versand: € 3,001
Bestellengesponserter Link
Trifilieff, Alexandre (Ed.):
Indacaterol. The First Once-daily Long-acting Beta2 Agonist for COPD. - gebunden oder broschiert

2014, ISBN: 3034807082

[EAN: 9783034807081], [PU: Basel, Birkhäuser Verlag.], METZLER, 235 mm x 155 mm. VII, 146 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, … Mehr…

Versandkosten: EUR 3.00 Antiquariat im Hufelandhaus GmbH vormals Lange & Springer, Berlin, Germany [2726420] [Rating: 5 (von 5)]
5
Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD - Trifilieff, Alexandre (Herausgeber)
Bestellen
bei Achtung-Buecher.de
€ 111,22
Versand: € 0,001
Bestellengesponserter Link
Trifilieff, Alexandre (Herausgeber):
Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD - gebunden oder broschiert

2013, ISBN: 3034807082

2014 Gebundene Ausgabe Pharmakologie, Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; lungfunction, mit Schutzumschlag 11, [PU:Springer Basel; Springer Basel AG]

Versandkosten:Versandkostenfrei innerhalb der BRD. (EUR 0.00) MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien

1Da einige Plattformen keine Versandkonditionen übermitteln und diese vom Lieferland, dem Einkaufspreis, dem Gewicht und der Größe des Artikels, einer möglichen Mitgliedschaft der Plattform, einer direkten Lieferung durch die Plattform oder über einen Drittanbieter (Marketplace), etc. abhängig sein können, ist es möglich, dass die von eurobuch angegebenen Versandkosten nicht mit denen der anbietenden Plattform übereinstimmen.

Bibliographische Daten des bestpassenden Buches

Details zum Buch
Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ss2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Detailangaben zum Buch - Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD (Milestones in Drug Therapy)


EAN (ISBN-13): 9783034807081
ISBN (ISBN-10): 3034807082
Gebundene Ausgabe
Erscheinungsjahr: 2014
Herausgeber: Trifilieff, Alexandre, Springer

Buch in der Datenbank seit 2014-09-14T18:56:16+02:00 (Berlin)
Detailseite zuletzt geändert am 2023-12-18T12:29:41+01:00 (Berlin)
ISBN/EAN: 9783034807081

ISBN - alternative Schreibweisen:
3-0348-0708-2, 978-3-0348-0708-1
Alternative Schreibweisen und verwandte Suchbegriffe:
Autor des Buches: alexandre, basel iii
Titel des Buches: acting first six, copd, milestones


Daten vom Verlag:

Autor/in: Alexandre Trifilieff
Titel: Milestones in Drug Therapy; Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD
Verlag: Springer; Springer Basel
146 Seiten
Erscheinungsjahr: 2013-11-27
Basel; CH
Gedruckt / Hergestellt in Niederlande.
Gewicht: 3,613 kg
Sprache: Englisch
106,99 € (DE)
109,99 € (AT)
118,00 CHF (CH)
POD
VII, 146 p. 41 illus., 21 illus. in color.

BB; Pharmacology/Toxicology; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; Lung function; Pneumology/Respiratory System; Pharmacology; Pneumology; Lungen- und Bronchialheilkunde; EA

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?  

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Summarizes preclinical and clinical data

A valuable source of information for scientists and clinicians

Contemporary monograph on the pharmacotherapy of COPD

Includes supplementary material: sn.pub/extras



Weitere, andere Bücher, die diesem Buch sehr ähnlich sein könnten:

Neuestes ähnliches Buch:
9783034807098 Indacaterol (Alexandre Trifilieff)


< zum Archiv...